In this study, we demonstrate that targeting BCL-2 with venetoclax and/or MCL-1 with S63845 is highly effective for reducing AML cells in culture, which is consistent with recent reports [11,21,22]. The gene discussed is BCL2; the disease is acute myeloid leukemia.